Clinical Trials Browser

Phase 3 × Unknown × Trastuzumab × Clear all

NCT05985187 2023-08-14

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Phase 3 Unknown

HER2-positive Breast Cancer

NCT03863223 2022-11-23

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Phase 3 Unknown

Breast Neoplasms

NCT04385563 2020-05-13

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Phase 3 Unknown

HER2-positive Metastatic Breast Cancer

NCT01104571 2018-09-17

EPHOS-B

Phase 3 Unknown

Breast Neoplasms

NCT03006614 2017-01-16

PERS

Phase 3 Unknown

Breast Neoplasms

NCT00486668 2016-06-06

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Phase 3 Unknown

Invasive Breast Cancer

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00712140 2011-09-02

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00430001 2008-05-09

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00637325 2008-03-17

TOP

Phase 3 Unknown

Neoplasm Metastasis